How MRNA stock performed in 2020

Shareholders were rewarded for holding through volatility.

| More on:
covid vaccine stocks represented by row of vials labelled covid vaccine

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Coming into 2020, Moderna Inc (NASDAQ: MRNA) was a $6.5 billion biotech with the goal of using messenger RNA (mRNA) -- the molecule that tells cells what proteins to make -- to fight and prevent disease. Not much was known about the company's technology or even the diseases its drugs would target, but that changed in 2020 as the company became one of the leaders in the fight against COVID-19

A breakout year

Moderna's stock rose 434% during 2020, but that number doesn't capture how eventful the year was, or the ups and downs shareholders experienced. After receiving funding from the Coalition for Epidemic Preparedness Innovations in late January, the company worked with the National Institute of Allergy and Infectious Diseases to deliver a COVID-19 vaccine candidate a month later.

Positive phase 1 data were released in mid-May, and management promptly raised $1.34 billion through a secondary share offering. On 30 November, the company provided analysis from phase 3 data showing its vaccine was 94.1% effective at preventing COVID-19. Three weeks later, on 18 December, the Food and Drug Administration (FDA) granted emergency use authorization (EUA). 

Although the stock's rise has been tremendous, its overall uneven progress offers a lesson in perseverance for shareholders. While everyone would welcome a more than 400% rise in a stock, holders had to endure a 25% sell-off (or more) four different times.

MRNA Chart

MRNA data by YCharts

Looking ahead, the company is well positioned for the future. Moderna had $3.3 billion in cash and investments on its balance sheet as of 30 September and recently increased the number of COVID-19 vaccine doses it expects to make in 2021 from 500 million to 600 million. The company has already supplied 18 million of an agreed-upon 200 million doses to the US Government and has additional deals with Canada, Israel, South Korea, and the European Commission, among other recipients . Despite this good news already priced into shares, the company has said it could produce as many as a billion doses this year. If so, last year's gains in the share price could continue through 2021.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Business woman with her arms folded stands in front of multiple screens.
International Stock News

How did the Magnificent 7 fare this reporting season?

Let's explore the highlights.

Read more »

A man looking at his laptop and thinking.
International Stock News

Amazon: A good quarter but some concerns

Here's our initial take on Amazon's financial report.

Read more »

Man looks up at apple on his head.
International Stock News

Apple: Growth in a difficult environment

Here's our initial take on Apple's financial report.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Why Microsoft stock popped this week

Microsoft stock was up by 9.5% this week.

Read more »

Electric vehicle such as Tesla being charged at charging station.
International Stock News

Tesla searches for Musk successor: Why this matters

Could Elon get the chainsaw from his own board?

Read more »

customers inside and outside a Microsoft retail store
International Stock News

Microsoft shares earnings report: What's the verdict?

Investors moved the Microsoft share price significantly.

Read more »

Warren Buffett
International Stock News

Countdown to Berkshire's AGM: What do investors expect to hear from Warren Buffett this year?

All eyes will be on Omaha, Nebraska this weekend.

Read more »

A smiling woman holds a Facebook like sign above her head.
International Stock News

Meta surges on blockbuster earnings report

It's a good day to be a Meta investor.

Read more »